source
- Angelini Pharma to Acquire Catalyst Pharmaceuticals for $4.1 B, Expanding U.S. Rare-Disease PortfolioAngelini Pharma announced Thursday it will purchase Catalyst Pharmaceuticals, a Florida‑based company focused on rare‑disease medicines, for about $4.1 billion in cash. The transaction values Cata…
- Sanofi asks FDA to withdraw teplizumab from fast-track review after internal disagreementSanofi has formally requested that the U.S. Food and Drug Administration remove its type 1 diabetes therapy, teplizumab, from the agency's new speedy review program. The request follows a disagree…